Researchers Turn to Cloud Computing as Genomic Sequencing Data Threatens to Overwhelm Traditional IT Systems
Seeking Young Scientists for Research in Space
Sounds of Science Podcasts
Tackling the Inevitability of Resistance One Genome at a Time
Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
FDA is getting ready to submit final recommendations for the fifth authorization of the Prescription Drug User Fee Act (PDUFA V) to Congress by January 2012. Details will be shaped by comments to the agency during a day-long public hearing on October 24. The new rules set up a process that emphasizes more communication early on between FDA and sponsors. The hope is that this move will increase the rate of drugs approved on the first try. PDUFA V also allows FDA to collect another $100 million from industry, to reach $3 billion a year. The agency expects to use the money to hire and train more staff to review applications. Read all the details here and tell us what you think about PDUFA V